Literature DB >> 3953869

Tricyclic nonresponders: phenomenology and treatment.

S P Roose, A H Glassman, B T Walsh, S Woodring.   

Abstract

In an attempt to identify characteristics of tricyclic antidepressant nonresponders, the authors reviewed the records of inpatients with unipolar, nondelusional depression who had received adequate treatment (confirmed by plasma level determination) with tricyclics. The 17 patients who failed to respond were compared to a group of tricyclic responders with respect to demographic and phenomenologic variables. Although the nonresponders tended to have more previous episodes of depression and higher anxiety scores on the pretreatment Hamilton scale than the responders, they could not be distinguished from the responders by clinical or demographic data. All of the patients who failed to respond to tricyclics subsequently responded to monoamine oxidase inhibitors and/or ECT.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3953869     DOI: 10.1176/ajp.143.3.345

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  9 in total

1.  What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?

Authors:  Jackie K Gollan; Maurizio Fava; Benji Kurian; Stephen R Wisniewski; A John Rush; Ella Daly; Sachiko Miyahara; Madhukar H Trivedi
Journal:  Depress Anxiety       Date:  2011-12-06       Impact factor: 6.505

2.  Baseline mood-state measures as predictors of antidepressant response to scopolamine.

Authors:  Maura L Furey; Allison C Nugent; Andrew M Speer; David A Luckenbaugh; Elana M Hoffman; Erica Frankel; Wayne C Drevets; Carlos A Zarate
Journal:  Psychiatry Res       Date:  2012-02-18       Impact factor: 3.222

Review 3.  Is the forced swimming test a suitable model for revealing antidepressant activity?

Authors:  F Borsini; A Meli
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Antidepressant failure: augmentation or substitution?

Authors:  R T Joffe; A J Levitt
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

Review 5.  Brofaromine--a review of its pharmacological properties and therapeutic use.

Authors:  H P Volz; C H Gleiter; P C Waldmeier; M Struck; H J Möller
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability.

Authors:  Andre R Brunoni; Renerio Fraguas; Felipe Fregni
Journal:  Ther Clin Risk Manag       Date:  2009-11-18       Impact factor: 2.423

7.  Olanzapine and fluoxetine combination in severe or resistant depression.

Authors:  R M Haridas; S R Parkar; Ram Ghulam; Gautam Amin; K G Thombre; A Srivastava; N Bhuvaneshwari; S Telang; Monika Obrah; Nandkishore Toraskar; R K Jalali; Kiran V Marthak
Journal:  Indian J Psychiatry       Date:  2003-10       Impact factor: 1.759

Review 8.  Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.

Authors:  Mazda Adli; Christopher Baethge; Andreas Heinz; Nicolas Langlitz; Michael Bauer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-29       Impact factor: 5.760

9.  Transdermal selegiline for the treatment of major depressive disorder.

Authors:  Kelly C Lee; Jack J Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.